Down 34.5% in One Month, Genfit Stock Continues to Decline This Friday
The Lille-based biotech company specializing in hepatic and metabolic diseases remains under pressure this Friday. The decline occurs in a rising Paris market, which amplifies the gap with the index. The stock remains below its main moving averages, approaching a monitored support level.
A Decline of 2.3% Against the Grain of a Rising SBF 120
Genfit is down 2.33% to €9.22 in early afternoon, while the SBF 120 advances 0.42%. The stock is among the index's biggest losers, in the wake of a very difficult month: the security loses nearly 35% over this period, after having nonetheless gained nearly 2% over the week. Market conditions remain marked by tension in French debt, with a 10-year OAT at 4.90% according to the latest reading from the Banque de France on October 1, 2026.
Declared net short positions reach 2.07% of capital, distributed among three funds, according to the disclosures reviewed. This accumulation appeared within 30 days, reflecting selling pressure that has recently established itself without being massive. This point is being monitored without being overinterpreted.
A Stock Below Its Three Moving Averages, Facing a Support Level at €8.92
The price is below the 20-day MA (gap of 18.84%), the 50-day MA (28.30%) and the 200-day MA (3.05%). The gap with the 200-day MA, at €9.51, is the tightest of the three: the stock has remained below this line since its recent decline, and the RSI at 34 signals a configuration near oversold territory. The support at €8.92 is located less than 4% from the current price.
On the analyst side, CIC Market Solutions maintained its buy rating on October 1 with a price target of €20, representing a potential upside of more than 100% from today's price. The €8.92 level is the nearest technical threshold.
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
SectorPharmacie et biotechnologies›Biotechnologies
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 36,4 millions d'euros
Quarterly revenue: 36,4 millions d'euros
Revenue growth: -7,1 %
Guidance from the release
« conforte GENFIT dans son anticipation de la réception possible d'un nouveau paiement d'étape commercial » ; « permettent un financement des activités au-delà de fin 2028 »
Risks mentioned
Dépendance envers Ipsen pour la majorité des revenus (redevances sur ventes d'Iqirvo), qui représente 99,7% des revenus de redevances
Paiements d'étape commerciaux futurs soumis à conditions réglementaires et commerciales incertaines
Besoin de financement au-delà de 2028 dépendant de la croissance des ventes d'élafibranor et de l'adoption commerciale des technologies NIS™
Opportunities identified
Croissance des ventes d'Iqirvo auprès d'Ipsen (188% YoY sur redevances) avec pic de ventes révisé à 1 milliard d'euros
Medicare a approuvé le remboursement du test NASHnext® en août 2026, ouvrant un marché potentiel estimé à plus de 1,5 milliard de dollars à horizon 2033
Lancement de trois essais cliniques de Phase 2 (ACLF, CCA) avec résultats attendus en 2027
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.